Ofev Capsule
NDC 0597-0145
Product Information
Ofev (nintedanib) is a NDA-approved product labeled by Boehringer Ingelheim Pharmaceuticals, Inc.. This medication is used to treat certain types of lung disease (idiopathic pulmonary fibrosis- IPF, interstitial lung disease). It is supplied as a brown capsule for oral administration. This product entry covers the primary NDC 0597-0145 and its associated package configuration. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Clinical Specifications
Labeler & Regulatory Data
Marketing Timeline
Product Characteristics
150
Code Structure Chart
Product Details
What is NDC 0597-0145?
What are the uses of this product?
What are Active Ingredients of this product?
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- NINTEDANIB ESYLATE (UNII: 42F62RTZ4G)
- NINTEDANIB (UNII: G6HRD2P839) (Active Moiety)
What is the NDC to RxNorm Crosswalk for this product?
- RxCUI: 1592742 - nintedanib 100 MG Oral Capsule
- RxCUI: 1592742 - nintedanib 100 MG (as nintedanib ethanesulfonate 120.4 MG) Oral Capsule
- RxCUI: 1592748 - Ofev 100 MG Oral Capsule
- RxCUI: 1592748 - nintedanib 100 MG Oral Capsule [Ofev]
- RxCUI: 1592748 - Ofev 100 MG (as nintedanib ethanesulfonate 120.4 MG) Oral Capsule
Which are the Pharmacologic Classes of this product?
* Please review the full disclaimer at the bottom of this page.
Patient Education
Nintedanib
Nintedanib is used to treat idiopathic pulmonary fibrosis (IPF; scarring of the lungs with an unknown cause). It is also used to treat certain types of chronic fibrosing interstitial lung diseases (ILD; an ongoing disease in which there is increased scarring of the lungs). Nintedanib is also used to slow the rate of decline in lung function in people with systemic sclerosis-associated interstitial lung disease (SSc-ILD; also known as scleroderma-associated ILD: a disease in which there is scarring of the lungs that is often fatal). Nintedanib is in a class of medications called kinase inhibitors. It works by blocking the action of enzymes involved in causing fibrosis.
[Learn More]
Cancer Chemotherapy
What is cancer chemotherapy?
Cancer chemotherapy is a type of cancer treatment. It uses medicines to destroy cancer cells.
Normally, the cells in your body grow and die in a controlled way. Cancer cells keep growing without control. Chemotherapy works by killing the cancer cells, stopping them from spreading, or slowing their growth.
Chemotherapy is used to:
- Treat cancer by curing the cancer, lessening the chance it will return, or stopping or slowing its growth.
- Ease cancer symptoms by shrinking tumors that are causing pain and other problems.
What are the side effects of chemotherapy?
Chemotherapy does not just destroy cancer cells. It can also harm some healthy cells, which causes side effects.
You may have a lot of side effects, some side effects, or none at all. It depends on the type and amount of chemotherapy you get and how your body reacts.
Some common side effects are:
- Mouth sores
- Fatigue
- Nausea and vomiting
- Pain
- Hair loss
There are ways to prevent or control some side effects. Talk with your health care provider about how to manage them. Healthy cells usually recover after chemotherapy is over, so most side effects gradually go away.
What can I expect when getting chemotherapy?
You may get chemotherapy in a hospital or at home, a doctor's office, or a medical clinic. You might be given the medicines by mouth, in a shot, as a cream, through a catheter, or intravenously (by IV).
Your treatment plan will depend on the type of cancer you have, which chemotherapy medicines are used, the treatment goals, and how your body responds to the medicines.
Chemotherapy may be given alone or with other treatments. You may get treatment every day, every week, or every month. You may have breaks between treatments so that your body has a chance to build new healthy cells.
NIH: National Cancer Institute
[Learn More]
* Please review the full disclaimer at the bottom of this page.